Bank of New York Mellon’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.12M | Buy |
76,756
+5,973
| +8% | +$80.3K | ﹤0.01% | 3297 |
|
|
2026
Q1 | $894K | Sell |
70,783
-1,805
| -2% | -$24.2K | ﹤0.01% | 3275 |
|
|
2025
Q4 | $1.14M | Buy |
72,588
+12,095
| +20% | +$154K | ﹤0.01% | 3158 |
|
|
2025
Q3 | $724K | Buy |
60,493
+5,019
| +9% | +$40.1K | ﹤0.01% | 3393 |
|
|
2025
Q2 | $419K | Buy |
55,474
+2,226
| +4% | +$13.4K | ﹤0.01% | 3609 |
|
|
2025
Q1 | $294K | Sell |
53,248
-3,872
| -7% | -$23.9K | ﹤0.01% | 3713 |
|
|
2024
Q4 | $328K | Sell |
57,120
-1,007
| -2% | -$9.65K | ﹤0.01% | 3733 |
|
|
2024
Q3 | $602K | Sell |
58,127
-15,714
| -21% | -$205K | ﹤0.01% | 3411 |
|
|
2024
Q2 | $958K | Buy |
73,841
+8,645
| +13% | +$117K | ﹤0.01% | 3229 |
|
|
2024
Q1 | $1.14M | Sell |
65,196
-7,430
| -10% | -$98.3K | ﹤0.01% | 3082 |
|
|
2023
Q4 | $683K | Sell |
72,626
-35,329
| -33% | -$329K | ﹤0.01% | 3386 |
|
|
2023
Q3 | $1.21M | Sell |
107,955
-57,838
| -35% | -$932K | ﹤0.01% | 3056 |
|
|
2023
Q2 | $3.55M | Sell |
165,793
-1,910
| -1% | -$56.3K | ﹤0.01% | 2507 |
|
|
2023
Q1 | $6.78M | Sell |
167,703
-716
| -0.4% | -$34.2K | ﹤0.01% | 2133 |
|
|
2022
Q4 | $7.83M | Sell |
168,419
-5,760
| -3% | -$263K | ﹤0.01% | 2066 |
|
|
2022
Q3 | $9.04M | Buy |
174,179
+6,384
| +4% | +$373K | ﹤0.01% | 1954 |
|
|
2022
Q2 | $7.93M | Sell |
167,795
-14,906
| -8% | -$809K | ﹤0.01% | 2072 |
|
|
2022
Q1 | $13M | Sell |
182,701
-12,760
| -7% | -$830K | ﹤0.01% | 1933 |
|
|
2021
Q4 | $14.6M | Buy |
195,461
+12,119
| +7% | +$951K | ﹤0.01% | 1898 |
|
|
2021
Q3 | $10.4M | Buy |
183,342
+6,969
| +4% | +$345K | ﹤0.01% | 2097 |
|
|
2021
Q2 | $7.76M | Sell |
176,373
-18,009
| -9% | -$882K | ﹤0.01% | 2269 |
|
|
2021
Q1 | $9.59M | Buy |
194,382
+1,288
| +0.7% | +$64.2K | ﹤0.01% | 2109 |
|
|
2020
Q4 | $8.13M | Sell |
193,094
-3,589
| -2% | -$158K | ﹤0.01% | 2109 |
|
|
2020
Q3 | $9M | Buy |
196,683
+5,311
| +3% | +$257K | ﹤0.01% | 1908 |
|
|
2020
Q2 | $9.61M | Buy |
191,372
+6,597
| +4% | +$341K | ﹤0.01% | 1862 |
|
|
2020
Q1 | $9.5M | Sell |
184,775
-4,542
| -2% | -$242K | ﹤0.01% | 1731 |
|
|
2019
Q4 | $11.7M | Sell |
189,317
-6,966
| -4% | -$432K | ﹤0.01% | 1879 |
|
|
2019
Q3 | $11.8M | Buy |
196,283
+749
| +0.4% | +$55.6K | ﹤0.01% | 1833 |
|
|
2019
Q2 | $16.5M | Sell |
195,534
-60,823
| -24% | -$5.47M | ﹤0.01% | 1668 |
|
|
2019
Q1 | $24.5M | Buy |
256,357
+1,594
| +0.6% | +$143K | 0.01% | 1435 |
|
|
2018
Q4 | $18M | Sell |
254,763
-1,683
| -0.7% | -$129K | 0.01% | 1540 |
|
|
2018
Q3 | $21.9M | Buy |
256,446
+9,799
| +4% | +$982K | 0.01% | 1571 |
|
|
2018
Q2 | $28.6M | Sell |
246,647
-2,729
| -1% | -$272K | 0.01% | 1380 |
|
|
2018
Q1 | $20.2M | Buy |
249,376
+75,262
| +43% | +$5.79M | 0.01% | 1565 |
|
|
2017
Q4 | $10.2M | Sell |
174,114
-5,832
| -3% | -$292K | ﹤0.01% | 1971 |
|
|
2017
Q3 | $8.42M | Sell |
179,946
-12,036
| -6% | -$484K | ﹤0.01% | 2068 |
|
|
2017
Q2 | $6.91M | Sell |
191,982
-7,096
| -4% | -$227K | ﹤0.01% | 2160 |
|
|
2017
Q1 | $6.13M | Buy |
199,078
+5,022
| +3% | +$156K | ﹤0.01% | 2229 |
|
|
2016
Q4 | $6.5M | Buy |
194,056
+2,899
| +2% | +$83.1K | ﹤0.01% | 2182 |
|
|
2016
Q3 | $5.09M | Buy |
191,157
+3,416
| +2% | +$79.3K | ﹤0.01% | 2229 |
|
|
2016
Q2 | $4.14M | Sell |
187,741
-36,440
| -16% | -$954K | ﹤0.01% | 2309 |
|
|
2016
Q1 | $6.58M | Sell |
224,181
-78,673
| -26% | -$2.19M | ﹤0.01% | 2047 |
|
|
2015
Q4 | $10M | Sell |
302,854
-22,436
| -7% | -$731K | ﹤0.01% | 1843 |
|
|
2015
Q3 | $11.8M | Buy |
325,290
+121,996
| +60% | +$5.24M | ﹤0.01% | 1768 |
|
|
2015
Q2 | $9.15M | Buy |
203,294
+40,904
| +25% | +$1.59M | ﹤0.01% | 2008 |
|
|
2015
Q1 | $4.97M | Buy |
162,390
+90,001
| +124% | +$3.5M | ﹤0.01% | 2318 |
|
|
2014
Q4 | $3.68M | Buy |
72,389
+5,172
| +8% | +$232K | ﹤0.01% | 2478 |
|
|
2014
Q3 | $2.66M | Buy |
67,217
+10,546
| +19% | +$420K | ﹤0.01% | 2680 |
|
|
2014
Q2 | $2.44M | Sell |
56,671
-32,020
| -36% | -$1.22M | ﹤0.01% | 2784 |
|
|
2014
Q1 | $3.55M | Buy |
88,691
+1,051
| +1% | +$38.2K | ﹤0.01% | 2507 |
|
|
2013
Q4 | $2.39M | Buy |
87,640
+20,239
| +30% | +$490K | ﹤0.01% | 2782 |
|
|
2013
Q3 | $1.54M | Buy |
67,401
+49,904
| +285% | +$954K | ﹤0.01% | 3006 |
|
|
2013
Q2 | $310K | Buy |
+17,497
| New | +$341K | ﹤0.01% | 3659 |
|
Other funds holding ENTA
CCIA
PAM
GCP
AA
Bank of New York Mellon's ENTA Position: Q2 2026 in Review
Bank of New York Mellon increased its Enanta Pharmaceuticals (ENTA) stake by 8.4% in Q2 2026, buying an estimated $80.3K and bringing the position to 76,756 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3297.
Bank of New York Mellon first reported a position in ENTA in Q2 2013 and has held it in 53 quarters since. The position peaked at $28.6M in Q2 2018. 43 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Bank of New York Mellon held 76,756 shares of Enanta Pharmaceuticals worth $1.12M as of Q2 2026.
- Bank of New York Mellon bought 5,973 Enanta Pharmaceuticals shares in Q2 2026, an estimated $80.3K.
- Enanta Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3297 holding.
- Bank of New York Mellon first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Enanta Pharmaceuticals position peaked at $28.6M in Q2 2018.
- 43 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.